AMRX logo

AMRX
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

4,030
Mkt Cap
$4.09B
Volume
690,042.00
52W High
$15.42
52W Low
$7.02
PE Ratio
57.90
AMRX Fundamentals
Price
$12.63
Prev Close
$12.82
Open
$12.84
50D MA
$13.17
Beta
1.08
Avg. Volume
2.27M
EPS (Annual)
$0.2218
P/B
-56.97
Rev/Employee
$355,148.23
$6,547.48
Loading...
Loading...
News
all
press releases
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·4h ago
News Placeholder
More News
News Placeholder
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results
Amneal's deal to buy Kashiv for up to $1.10B aids biosimilar push. The company posts strong preliminary Q1 results and raises 2026 EPS guidance.
Zacks·4h ago
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) Issues Earnings Results
Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) released its earnings results on Wednesday. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.11. Amneal Pharmaceuticals had a negative return on equity of 228.24% and a net...
MarketBeat·1d ago
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) Updates Q1 2026 Earnings Guidance
Amneal Pharmaceuticals (NASDAQ:AMRX) updated its first quarter 2026 earnings guidance. The company provided EPS guidance of 0.270-0.270 for the period, compared to the consensus estimate of 0.160...
MarketBeat·1d ago
News Placeholder
Futures Rise After Trump Extends Ceasefire Even As Brent Tops $100
false
Zero Hedge·1d ago
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2026 Earnings Guidance
Amneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2026 earnings guidance. The company provided EPS guidance of 0.950-1.050 for the period, compared to the consensus estimate of 0.950. The company...
MarketBeat·1d ago
News Placeholder
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +63.64% and +1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
Why Is Amneal Pharmaceuticals Stock Gaining Today?
Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.read more...
Benzinga·1d ago
News Placeholder
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
Kashiv BioSciences, LLC (Kashiv), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (Amneal). The transaction is subject to...
Business Wire·1d ago
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Down 5.5% - Time to Sell?
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Down 5.5% - What's Next...
MarketBeat·3d ago
<
1
2
...
>

Latest AMRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.